CQCIL Stock Overview
Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Cipla Quality Chemical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | USh53.00 |
| 52 Week High | USh70.00 |
| 52 Week Low | USh52.00 |
| Beta | -0.21 |
| 1 Month Change | 0.95% |
| 3 Month Change | 0.95% |
| 1 Year Change | -24.29% |
| 3 Year Change | -41.11% |
| 5 Year Change | -69.49% |
| Change since IPO | -79.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| CQCIL | UG Pharmaceuticals | UG Market | |
|---|---|---|---|
| 7D | 1.0% | -2.8% | 0.6% |
| 1Y | -24.3% | 9.9% | 8.2% |
Return vs Industry: CQCIL underperformed the UG Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: CQCIL underperformed the UG Market which returned 10% over the past year.
Price Volatility
| CQCIL volatility | |
|---|---|
| CQCIL Average Weekly Movement | 0.5% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 1.0% |
| 10% most volatile stocks in UG Market | 3.0% |
| 10% least volatile stocks in UG Market | 0.6% |
Stable Share Price: CQCIL has not had significant price volatility in the past 3 months.
Volatility Over Time: CQCIL's weekly volatility (0%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Ajay Pal | www.ciplaqcil.co.ug |
Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines. The company offers Duovir-N; Lamivudine and Zidovudine; Efavir 60; Duomune; Nevirapine; Efavirenz, Lamivudine, and Tenofovir; and Dolutegravir, Lamivudine, and Tenofovir tablets for the treatment of HIV infection. It also offers Lumartem/Lumet tablets for the treatment of malaria; and Texavir and Zentair for the treatment of Hepatitis B. The company was formerly known as Quality Chemicals Industries Limited and changed its name to Cipla Quality Chemical Industries Limited in March 2014.
Cipla Quality Chemical Industries Limited Fundamentals Summary
| CQCIL fundamental statistics | |
|---|---|
| Market cap | USh193.55b |
| Earnings (TTM) | USh18.99b |
| Revenue (TTM) | USh221.47b |
10.2x
P/E Ratio0.9x
P/S RatioIs CQCIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CQCIL income statement (TTM) | |
|---|---|
| Revenue | USh221.47b |
| Cost of Revenue | USh154.46b |
| Gross Profit | USh67.01b |
| Other Expenses | USh48.02b |
| Earnings | USh18.99b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.20 |
| Gross Margin | 30.26% |
| Net Profit Margin | 8.57% |
| Debt/Equity Ratio | 3.2% |
How did CQCIL perform over the long term?
See historical performance and comparison